{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:10:16Z","timestamp":1790669416765,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2020-MS-178"],"award-info":[{"award-number":["2020-MS-178"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancer\/testis antigens (CTAs) participate in the regulation of malignant biological behaviors in breast cancer. However, the function and mechanism of KK-LC-1, a member of the CTA family, in breast cancer are still unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Bioinformatic tools, immunohistochemistry, and western blotting were utilized to detect the expression of KK-LC-1 in breast cancer and to explore the prognostic effect of KK-LC-1 expression in breast cancer patients. Cell function assays, animal assays, and next-generation sequencing were utilized to explore the function and mechanism of KK-LC-1 in the malignant biological behaviors of triple-negative breast cancer. Small molecular compounds targeting KK-LC-1 were also screened and drug susceptibility testing was performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>KK-LC-1 was significantly highly expressed in triple-negative breast cancer tissues than in normal breast tissues. KK-LC-1 high expression was related to poor survival outcomes in patients with breast cancer. In vitro studies suggested that KK-LC-1 silencing can inhibit triple-negative breast cancer cell proliferation, invasion, migration, and scratch healing ability, increase cell apoptosis ratio, and arrest the cell cycle in the G0\u2013G1 phase. In vivo studies have suggested that KK-LC-1 silencing decreases tumor weight and volume in nude mice. Results showed that KK-CL-1 can regulate the malignant biological behaviors of triple-negative breast cancer via the MAL2\/MUC1-C\/PI3K\/AKT\/mTOR pathway. The small-molecule compound Z839878730 had excellent KK-LC-1 targeting ability and cancer cell killing ability. The EC<jats:sub>50<\/jats:sub> value was 9.7\u00a0\u03bcM for MDA-MB-231 cells and 13.67\u00a0\u00b5M for MDA-MB-468 cells. Besides, Z839878730 has little tumor-killing effect on human normal mammary epithelial cells MCF10A and can inhibit the malignant biological behaviors of triple-negative breast cancer cells by MAL2\/MUC1-C\/PI3K\/AKT\/mTOR pathway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that KK-LC-1 may serve as a novel therapeutic target for triple-negative breast cancer. Z839878730, which targets KK-LC-1, presents a new path for breast cancer clinical treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04030-9","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:14:03Z","timestamp":1679861643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-6112","authenticated-orcid":false,"given":"Xudong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"3","key":"4030_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4030_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"4030_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"4030_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, et al. Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer. Cancer Cell. 2019;36(5):545\u201358.","journal-title":"Cancer Cell"},{"key":"4030_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102855","volume":"145","author":"JL da Silva","year":"2020","unstructured":"da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC. Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol. 2020;145: 102855.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"4030_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/ijc.31950","volume":"144","author":"ALV Johansson","year":"2019","unstructured":"Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer. 2019;144(6):1251\u201361.","journal-title":"Int J Cancer"},{"issue":"7578","key":"4030_CR7","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1038\/527S120a","volume":"527","author":"C Woolston","year":"2015","unstructured":"Woolston C. Breast cancer: 4 big questions. Nature. 2015;527(7578):S120.","journal-title":"Nature"},{"issue":"9","key":"4030_CR8","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1158\/0008-5472.CAN-05-3840","volume":"66","author":"T Fukuyama","year":"2006","unstructured":"Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T, et al. Identification of a new cancer\/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 2006;66(9):4922\u20138.","journal-title":"Cancer Res"},{"issue":"4","key":"4030_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1158\/2326-6066.CIR-13-0088","volume":"2","author":"J Yao","year":"2014","unstructured":"Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, et al. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res. 2014;2(4):371\u20139.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4030_CR10","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1038\/s41598-018-24514-9","volume":"8","author":"T Fukuyama","year":"2018","unstructured":"Fukuyama T, Futawatari N, Yamamura R, Yamazaki T, Ichiki Y, Ema A, et al. Expression of KK-LC-1, a cancer\/testis antigen, at non-tumour sites of the stomach carrying a tumour. Sci Rep. 2018;8(1):6131.","journal-title":"Sci Rep"},{"issue":"46","key":"4030_CR11","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.3748\/wjg.v23.i46.8200","volume":"23","author":"N Futawatari","year":"2017","unstructured":"Futawatari N, Fukuyama T, Yamamura R, Shida A, Takahashi Y, Nishi Y, et al. Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen. World J Gastroenterol. 2017;23(46):8200\u20136.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4030_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2009.05.010","volume":"68","author":"Y Shigematsu","year":"2010","unstructured":"Shigematsu Y, Hanagiri T, Shiota H, Kuroda K, Baba T, Mizukami M, et al. Clinical significance of cancer\/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer. 2010;68(1):105\u201310.","journal-title":"Lung Cancer"},{"issue":"3","key":"4030_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12581","volume":"52","author":"Z Chen","year":"2019","unstructured":"Chen Z, Zuo X, Pu L, Zhang Y, Han G, Zhang L, et al. Hypomethylation-mediated activation of cancer\/testis antigen KK-LC-1 facilitates hepatocellular carcinoma progression through activating the Notch1\/Hes1 signalling. Cell Prolif. 2019;52(3): e12581.","journal-title":"Cell Prolif"},{"issue":"3","key":"4030_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.21873\/invivo.11073","volume":"31","author":"T Fukuyama","year":"2017","unstructured":"Fukuyama T, Futawatari N, Ichiki Y, Shida A, Yamazaki T, Nishi Y, et al. Correlation between expression of the cancer\/testis antigen KK-LC-1 and Helicobacter pylori infection in gastric cancer. In Vivo. 2017;31(3):403\u20137.","journal-title":"In Vivo"},{"key":"4030_CR15","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.2147\/OTT.S159491","volume":"11","author":"S Jin","year":"2018","unstructured":"Jin S, Cao S, Li J, Meng Q, Wang C, Yao L, et al. Cancer\/testis antigens (CTAs) expression in resected lung cancer. Onco Targets Ther. 2018;11:4491\u20139.","journal-title":"Onco Targets Ther"},{"issue":"69","key":"4030_CR16","doi-asserted-by":"publisher","first-page":"113373","DOI":"10.18632\/oncotarget.23009","volume":"8","author":"AS Cohen","year":"2017","unstructured":"Cohen AS, Khalil FK, Welsh EA, Schabath MB, Enkemann SA, Davis A, et al. Cell-surface marker discovery for lung cancer. Oncotarget. 2017;8(69):113373\u2013402.","journal-title":"Oncotarget"},{"issue":"10","key":"4030_CR17","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.21873\/anticanres.12937","volume":"38","author":"Y Kondo","year":"2018","unstructured":"Kondo Y, Fukuyama T, Yamamura R, Futawatari N, Ichiki Y, Tanaka Y, et al. Detection of KK-LC-1 protein, a cancer\/testis antigen, in patients with breast cancer. Anticancer Res. 2018;38(10):5923\u20138.","journal-title":"Anticancer Res"},{"issue":"28","key":"4030_CR18","doi-asserted-by":"publisher","first-page":"25356","DOI":"10.18632\/oncotarget.4516","volume":"6","author":"C Paret","year":"2015","unstructured":"Paret C, Simon P, Vormbrock K, Bender C, Kolsch A, Breitkreuz A, et al. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. Oncotarget. 2015;6(28):25356\u201367.","journal-title":"Oncotarget"},{"issue":"3","key":"4030_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/ijc.21352","volume":"118","author":"A Mischo","year":"2006","unstructured":"Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer. 2006;118(3):696\u2013703.","journal-title":"Int J Cancer"},{"issue":"2","key":"4030_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ijc.22309","volume":"120","author":"C Groeper","year":"2007","unstructured":"Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, et al. Cancer\/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer. 2007;120(2):337\u201343.","journal-title":"Int J Cancer"},{"issue":"2","key":"4030_CR21","first-page":"557","volume":"21","author":"G Zhong","year":"2020","unstructured":"Zhong G, Lou W, Shen Q, Yu K, Zheng Y. Identification of key genes as potential biomarkers for triplenegative breast cancer using integrating genomics analysis. Mol Med Rep. 2020;21(2):557\u201366.","journal-title":"Mol Med Rep"},{"key":"4030_CR22","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/cam4.1601","volume":"7","author":"Z Ye","year":"2018","unstructured":"Ye Z, Liang Y, Ma Y, Lin B, Cao L, Wang B, et al. Targeted photodynamic therapy of cancer using a novel gallium (III) tris (ethoxycarbonyl) corrole conjugated-mAb directed against cancer\/testis antigens 83. Cancer Med. 2018;7:3057.","journal-title":"Cancer Med"},{"issue":"26","key":"4030_CR23","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.18632\/oncotarget.26808","volume":"10","author":"J Kaufmann","year":"2019","unstructured":"Kaufmann J, Wentzensen N, Brinker TJ, Grabe N. Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. Oncotarget. 2019;10(26):2515\u201329.","journal-title":"Oncotarget"},{"issue":"10","key":"4030_CR24","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.4161\/cc.10.10.15703","volume":"10","author":"Z Jiang","year":"2011","unstructured":"Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10(10):1563\u201370.","journal-title":"Cell Cycle"},{"issue":"24","key":"4030_CR25","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.3390\/cancers13246209","volume":"13","author":"L He","year":"2021","unstructured":"He L, Wick N, Germans SK, Peng Y. The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer. Cancers. 2021;13(24):6209.","journal-title":"Cancers"},{"key":"4030_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2121-10-7","volume":"10","author":"S Fanayan","year":"2009","unstructured":"Fanayan S, Shehata M, Agterof AP, McGuckin MA, Alonso MA, Byrne JA. Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. BMC Cell Biol. 2009;10:7.","journal-title":"BMC Cell Biol"},{"issue":"2","key":"4030_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bbrc.2018.08.187","volume":"504","author":"A Bhandari","year":"2018","unstructured":"Bhandari A, Shen Y, Sindan N, Xia E, Gautam B, Lv S, et al. MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines. Biochem Biophys Res Commun. 2018;504(2):434\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"4030_CR28","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/onc.2012.158","volume":"32","author":"DW Kufe","year":"2013","unstructured":"Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013;32(9):1073\u201381.","journal-title":"Oncogene"},{"issue":"5","key":"4030_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.acthis.2016.05.002","volume":"118","author":"M Jurikova","year":"2016","unstructured":"Jurikova M, Danihel L, Polak S, Varga I. Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016;118(5):544\u201352.","journal-title":"Acta Histochem"},{"issue":"4","key":"4030_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.breast.2008.02.002","volume":"17","author":"R Stuart-Harris","year":"2008","unstructured":"Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;17(4):323\u201334.","journal-title":"Breast"},{"issue":"1","key":"4030_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12906-022-03533-0","volume":"22","author":"MA Khan","year":"2022","unstructured":"Khan MA, Singh R, Siddiqui S, Ahmad I, Ahmad R, Upadhyay S, et al. Anticancer potential of Phoenix dactylifera L seed extract in human cancer cells and pro-apoptotic effects mediated through caspase-3 dependent pathway in human breast cancer MDA-MB-231 cells: an in vitro and in silico investigation. BMC Complement Med Ther. 2022;22(1):68.","journal-title":"BMC Complement Med Ther."},{"issue":"8","key":"4030_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.201800045","volume":"15","author":"IM Abdel-Salam","year":"2018","unstructured":"Abdel-Salam IM, Ashmawy AM, Hilal AM, Eldahshan OA, Ashour M. Chemical composition of aqueous ethanol extract of luffa cylindrica leaves and its effect on representation of caspase-8, caspase-3, and the proliferation marker Ki67 in intrinsic molecular subtypes of breast cancer in vitro. Chem Biodivers. 2018;15(8): e1800045.","journal-title":"Chem Biodivers"},{"issue":"11","key":"4030_CR33","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/onc.2010.518","volume":"30","author":"S Tabaries","year":"2011","unstructured":"Tabaries S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene. 2011;30(11):1318\u201328.","journal-title":"Oncogene"},{"issue":"15","key":"4030_CR34","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/MCB.00299-12","volume":"32","author":"S Tabaries","year":"2012","unstructured":"Tabaries S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, et al. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol. 2012;32(15):2979\u201391.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"4030_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.molonc.2013.10.002","volume":"8","author":"S Kimbung","year":"2014","unstructured":"Kimbung S, Kovacs A, Bendahl PO, Malmstrom P, Ferno M, Hatschek T, et al. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol. 2014;8(1):119\u201328.","journal-title":"Mol Oncol"},{"issue":"12","key":"4030_CR36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrg3813","volume":"15","author":"S Gerstberger","year":"2014","unstructured":"Gerstberger S, Hafner M, Tuschl T. A census of human RNA-binding proteins. Nat Rev Genet. 2014;15(12):829\u201345.","journal-title":"Nat Rev Genet"},{"key":"4030_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.07.001","volume":"203","author":"S Mohibi","year":"2019","unstructured":"Mohibi S, Chen X, Zhang J. Cancer the\u2019RBP\u2019eutics-RNA-binding proteins as therapeutic targets for cancer. Pharmacol Ther. 2019;203: 107390.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"4030_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.trecan.2017.05.003","volume":"3","author":"B Pereira","year":"2017","unstructured":"Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3(7):506\u201328.","journal-title":"Trends Cancer"},{"issue":"3","key":"4030_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1520","volume":"10","author":"K Masuda","year":"2019","unstructured":"Masuda K, Kuwano Y. Diverse roles of RNA-binding proteins in cancer traits and their implications in gastrointestinal cancers. Wiley Interdiscip Rev RNA. 2019;10(3): e1520.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"4030_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-0716-0743-5_7","volume":"2170","author":"EL Sternburg","year":"2021","unstructured":"Sternburg EL, Karginov FV. Analysis of RBP regulation and co-regulation of mRNA 3\u2019 UTR regions in a luciferase reporter system. Methods Mol Biol. 2021;2170:101\u201315.","journal-title":"Methods Mol Biol"},{"key":"4030_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.omtn.2020.10.011","volume":"23","author":"Q Guo","year":"2021","unstructured":"Guo Q, Wu Y, Guo X, Cao L, Xu F, Zhao H, et al. The RNA-binding protein CELF2 inhibits ovarian cancer progression by stabilizing FAM198B. Mol Ther Nucleic Acids. 2021;23:169\u201384.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"4030_CR42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10555-016-9648-7","volume":"35","author":"CL Chaffer","year":"2016","unstructured":"Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645\u201354.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"4030_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cac2.12138","volume":"41","author":"G Pan","year":"2021","unstructured":"Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun. 2021;41(3):199\u2013217.","journal-title":"Cancer Commun"},{"issue":"7774","key":"4030_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41586-019-1526-3","volume":"573","author":"V Padmanaban","year":"2019","unstructured":"Padmanaban V, Krol I, Suhail Y, Szczerba BM, Aceto N, Bader JS, et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature. 2019;573(7774):439\u201344.","journal-title":"Nature"},{"issue":"18","key":"4030_CR45","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","volume":"68","author":"A Satelli","year":"2011","unstructured":"Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033\u201346.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"4030_CR46","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41418-018-0158-8","volume":"26","author":"N Zhang","year":"2019","unstructured":"Zhang N, Zhang H, Liu Y, Su P, Zhang J, Wang X, et al. SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1\/2. Cell Death Differ. 2019;26(5):843\u201359.","journal-title":"Cell Death Differ"},{"key":"4030_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biocel.2018.12.001","volume":"107","author":"R Butti","year":"2019","unstructured":"Butti R, Gunasekaran VP, Kumar TVS, Banerjee P, Kundu GC. Breast cancer stem cells: Biology and therapeutic implications. Int J Biochem Cell Biol. 2019;107:38\u201352.","journal-title":"Int J Biochem Cell Biol"},{"key":"4030_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.semcancer.2018.07.007","volume":"53","author":"J Dittmer","year":"2018","unstructured":"Dittmer J. Breast cancer stem cells: features, key drivers and treatment options. Semin Cancer Biol. 2018;53:59\u201374.","journal-title":"Semin Cancer Biol"},{"key":"4030_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.semcancer.2016.09.001","volume":"40\u201341","author":"PR Dandawate","year":"2016","unstructured":"Dandawate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy. Semin Cancer Biol. 2016;40\u201341:192\u2013208.","journal-title":"Semin Cancer Biol"},{"issue":"14","key":"4030_CR50","doi-asserted-by":"publisher","first-page":"E2047","DOI":"10.1073\/pnas.1602883113","volume":"113","author":"C Zhang","year":"2016","unstructured":"Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016;113(14):E2047\u201356.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4030_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13046-018-0975-0","volume":"37","author":"V Ciccone","year":"2018","unstructured":"Ciccone V, Terzuoli E, Donnini S, Giachetti A, Morbidelli L, Ziche M. Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid\/HIF-1alpha\/VEGF signalling in MCF-7 breast cancer cells. J Exp Clin Cancer Res. 2018;37(1):311.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4030_CR52","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1038\/s41467-019-13700-6","volume":"10","author":"JM Yu","year":"2019","unstructured":"Yu JM, Sun W, Wang ZH, Liang X, Hua F, Li K, et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription. Nat Commun. 2019;10(1):5720.","journal-title":"Nat Commun"},{"issue":"9","key":"4030_CR53","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1172\/JCI138577","volume":"130","author":"H Lu","year":"2020","unstructured":"Lu H, Xie Y, Tran L, Lan J, Yang Y, Murugan NL, et al. Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness. J Clin Invest. 2020;130(9):4607\u201323.","journal-title":"J Clin Invest"},{"issue":"1","key":"4030_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-016-0570-y","volume":"16","author":"A Al-Dhfyan","year":"2017","unstructured":"Al-Dhfyan A, Alhoshani A, Korashy HM. Aryl hydrocarbon receptor\/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and beta-Catenin and Akt activation. Mol Cancer. 2017;16(1):14.","journal-title":"Mol Cancer"},{"issue":"6","key":"4030_CR55","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/onc.2014.5","volume":"34","author":"M Bartucci","year":"2015","unstructured":"Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015;34(6):681\u201390.","journal-title":"Oncogene"},{"issue":"1","key":"4030_CR56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140837","volume":"131","author":"Y Fang","year":"2021","unstructured":"Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z, et al. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2021;131(1): e140837.","journal-title":"J Clin Invest"},{"issue":"1","key":"4030_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144344","volume":"131","author":"D Dersh","year":"2021","unstructured":"Dersh D, Yewdell JW. Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation. J Clin Invest. 2021;131(1): e144344.","journal-title":"J Clin Invest"},{"key":"4030_CR58","doi-asserted-by":"publisher","first-page":"5557873","DOI":"10.1155\/2021\/5557873","volume":"2021","author":"Y Zhong","year":"2021","unstructured":"Zhong Y, Zhuang Z, Mo P, Shang Q, Lin M, Gong J, et al. Overexpression of MAL2 correlates with immune infiltration and poor prognosis in breast cancer. Evid Based Complement Alternat Med. 2021;2021:5557873.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"4030_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","volume":"78","author":"T Maeda","year":"2018","unstructured":"Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, et al. MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Cancer Res. 2018;78(1):205\u201315.","journal-title":"Cancer Res"},{"issue":"6","key":"4030_CR60","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","volume":"22","author":"S Loi","year":"2016","unstructured":"Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, et al. RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 2016;22(6):1499\u2013509.","journal-title":"Clin Cancer Res"},{"key":"4030_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2018","unstructured":"Krishnamurthy N, Kurzrock R. Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50\u201360.","journal-title":"Cancer Treat Rev"},{"issue":"25","key":"4030_CR62","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.2174\/0929867328666201207202012","volume":"28","author":"F Shao","year":"2021","unstructured":"Shao F, Pang X, Baeg GH. Targeting the JAK\/STAT Signaling Pathway for Breast Cancer. Curr Med Chem. 2021;28(25):5137\u201351.","journal-title":"Curr Med Chem"},{"issue":"1","key":"4030_CR63","first-page":"98","volume":"1","author":"V Apostolopoulos","year":"1999","unstructured":"Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr Opin Mol Ther. 1999;1(1):98\u2013103.","journal-title":"Curr Opin Mol Ther"},{"issue":"1","key":"4030_CR64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/ijms22010173","volume":"22","author":"D Miricescu","year":"2020","unstructured":"Miricescu D, Totan A, Stanescu S II, Badoiu SC, Stefani C, Greabu M. PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22(1):173.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4030_CR65","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10555-016-9637-x","volume":"35","author":"A Guerrero-Zotano","year":"2016","unstructured":"Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K\/AKT\/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35(4):515\u201324.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"4030_CR66","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","volume":"169","author":"RLB Costa","year":"2018","unstructured":"Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397\u2013406.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"4030_CR67","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.yexcr.2009.02.011","volume":"315","author":"G Horn","year":"2009","unstructured":"Horn G, Gaziel A, Wreschner DH, Smorodinsky NI, Ehrlich M. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res. 2009;315(8):1490\u2013504.","journal-title":"Exp Cell Res"},{"issue":"5","key":"4030_CR68","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/1535-7163.MCT-10-1050","volume":"10","author":"D Raina","year":"2011","unstructured":"Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011;10(5):806\u201316.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"4030_CR69","doi-asserted-by":"publisher","first-page":"L686","DOI":"10.1152\/ajplung.00423.2006","volume":"293","author":"K Kato","year":"2007","unstructured":"Kato K, Lu W, Kai H, Kim KC. Phosphoinositide 3-kinase is activated by MUC1 but not responsible for MUC1-induced suppression of Toll-like receptor 5 signaling. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L686\u201392.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"11","key":"4030_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028234","volume":"6","author":"M Kosugi","year":"2011","unstructured":"Kosugi M, Ahmad R, Alam M, Uchida Y, Kufe D. MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS ONE. 2011;6(11): e28234.","journal-title":"PLoS ONE"},{"issue":"17","key":"4030_CR71","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/onc.2011.410","volume":"31","author":"JK Woo","year":"2012","unstructured":"Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH, Seo HS, et al. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. Oncogene. 2012;31(17):2187\u201398.","journal-title":"Oncogene"},{"issue":"8","key":"4030_CR72","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"4030_CR73","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"4030_CR74","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11912-019-0846-7","volume":"21","author":"H Ellis","year":"2019","unstructured":"Ellis H, Ma CX. PI3K inhibitors in breast cancer therapy. Curr Oncol Rep. 2019;21(12):110.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"4030_CR75","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s42003-021-02189-9","volume":"4","author":"S Tabaries","year":"2021","unstructured":"Tabaries S, Annis MG, Lazaris A, Petrillo SK, Huxham J, Abdellatif A, et al. Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. Commun Biol. 2021;4(1):657.","journal-title":"Commun Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04030-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04030-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04030-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:18:58Z","timestamp":1679861938000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04030-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4030"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04030-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the China Medical University Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"These authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}